Video interviews; CLL 'Hot Topics and Maturing... - CLL Support

CLL Support

23,253 members39,949 posts

Video interviews; CLL 'Hot Topics and Maturing Data' ASH 2019: Prof John Gribben, Prof Pete Hillmen, Dr George Follows & Dr Renata Walewska

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin
5 Replies

In December, the Leukaemia Care Patient Advocacy team attended the annual American Society of Hematology (ASH) conference in Florida, where the latest research in haematology was presented.

Whilst there, the team spoke to a number of UK CLL experts who kindly provided patients with summary updates of the latest advances in the treatment of CLL.

I recall diagnosis and my early life with CLL 11 years ago, how different the landscape is today. That early hope and promise of change is fast becoming a reality as more treatment stepping stones provide a path into the future.

Professor John Gribben discusses, hot topics in CLL from ASH 2019. How the variety of new agents and the consolidation of evidence and knowledge is aiding the shift away from chemotherapy based treatments to novel targeted therapy. youtu.be/Qs2qG3Uv0Mw

Professor Pete Hillmen discusses how CLL treatment is fast changing. Maturing trial data is evidencing benefits over chemotherapy for the combinations of different targeted non chemo-therapies for use as fixed duration treatments for patients in 1st line and relapsed settings. With data from trials of next generation targeted therapies showing great promise increasing future options. youtu.be/HRnlQvHrgA0

Dr George Follows describes how the ELEVATE clinical trial, presented at ASH, shows that acalabrutinib is an effective treatment option for chronic lymphocytic leukaemia (CLL) patients, and explains his hopes for its future use in the UK. youtu.be/8ss7J1VMCIQ

Renata Walewska discusses the position of chemotherapy and novel inhibitors, the combinations of inhibitors. Sequencing and duration questions for use of these therapies, MRD as a treatment objective and suitability of fixed duration novel combination therapies versus continuous therapy for high risk patients. youtu.be/PrxeGl9GPe8

Written by
HAIRBEAR_UK profile image
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
Read more about...
5 Replies
Ernest2 profile image
Ernest2

Many thanks Nick, what a great line up, and set of videos.

Best wishes,

Ernest

Wroxham profile image
Wroxham

Thanks Nick

Sue

Etoile7 profile image
Etoile7

Hi Nick, many thanks for that. One question: do you know which paper,abstract or presentation Prof. Hillmen is referring to when talking about an important VO update?

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin in reply toEtoile7

Hi Etoile7

CLL14, chlorambucil plus obinutuzumab versus venetoclax plus obintuzumab,

Before ASH 2019 only 24 month follow-up data was available which correlated to only one year post treatment as venetoclax plus obinutuzimb is a 12 month therapy .

Data was published at ASH 2019 extending this by another 12 months, to 36 months total follow up data; equating to 2 years post treatment follow up data.

Etoile7 profile image
Etoile7 in reply toHAIRBEAR_UK

cheers....

Not what you're looking for?

You may also like...

ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista

Prof Nicole Lamanna - ASH 2019 - Maturing CLL clinical trial data Dr. Nicole Lamanna, Associate...
HAIRBEAR_UK profile image
Founder Admin

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

From Blood Cancer Journal 29th April 2021 Four strategies have been tested in recent years...
Jm954 profile image
Administrator

New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors

MS-553 is a protein kinase C-beta (PKCß) inhibitor designed to be an alternative treatment option...
spi3 profile image

Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL

Targeted Oncology May 4th 2021 In an interview with Targeted Oncology, Dr Mato , a hematologc...
Jm954 profile image
Administrator

BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'

In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
CLLerinOz profile image
Administrator